Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Historic Liabilities from Discontinued Operations for Avalo Therapeutics (AVTX) over the last 4 years, with Q3 2021 value amounting to $10000.0.

  • Avalo Therapeutics' Liabilities from Discontinued Operations fell 9982.86% to $10000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $10000.0, marking a year-over-year decrease of 9982.86%. This contributed to the annual value of $1.3 million for FY2020, which is 6553.6% down from last year.
  • Per Avalo Therapeutics' latest filing, its Liabilities from Discontinued Operations stood at $10000.0 for Q3 2021, which was down 9982.86% from $98000.0 recorded in Q2 2021.
  • Avalo Therapeutics' Liabilities from Discontinued Operations' 5-year high stood at $21.0 million during Q4 2018, with a 5-year trough of $10000.0 in Q3 2021.
  • Its 4-year average for Liabilities from Discontinued Operations is $4.9 million, with a median of $3.9 million in 2019.
  • In the last 5 years, Avalo Therapeutics' Liabilities from Discontinued Operations crashed by 6553.6% in 2020 and then crashed by 9982.86% in 2021.
  • Avalo Therapeutics' Liabilities from Discontinued Operations (Quarter) stood at $21.0 million in 2018, then tumbled by 81.49% to $3.9 million in 2019, then plummeted by 65.54% to $1.3 million in 2020, then crashed by 99.25% to $10000.0 in 2021.
  • Its Liabilities from Discontinued Operations stands at $10000.0 for Q3 2021, versus $98000.0 for Q2 2021 and $209000.0 for Q1 2021.